Substance / Medication

Patisiran

Overview

Active Ingredient
patisiran
RxNorm CUI
2053490

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review.
Karimi Mohammad Amin, Esmaeilpour Moallem Fatemeh, Gholami Chahkand Mohammad Sadra et al. · Front Neurol · 2024
PMID: 39286810Meta-AnalysisFull text (PMC)
Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis.
Mesquita Claudio Tinoco, Schwartzmann Pedro, Correia Edileide Barros et al. · Arq Bras Cardiol · 2025
PMID: 40243852RCTFull text (PMC)
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer Mathew S, Kale Parag, Fontana Marianna et al. · N Engl J Med · 2023
PMID: 37888916RCTFull text (PMC)
Patisiran in ATTRv amyloidosis with polyneuropathy: "PatisiranItaly" multicenter observational study.
Di Stefano Vincenzo, Guaraldi Pietro, Romano Angela et al. · J Neurol · 2025
PMID: 39954098ObservationalFull text (PMC)
Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
Gentile Luca, Mazzeo Anna, Briani Chiara et al. · Neurol Sci · 2024
PMID: 38622453ObservationalFull text (PMC)
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Gorevic Peter, Franklin Jaclyn, Chen Jihong et al. · Expert Opin Pharmacother · 2021
PMID: 32892660Observational
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Planté-Bordeneuve Violaine, Lin Hollis, Gollob Jared et al. · Expert Opin Pharmacother · 2019
PMID: 30489166Observational
Patisiran exposure in early pregnancy: a case report.
Loser Valentin, Baumgartner Thomas, Legardeur Hélène et al. · Ther Adv Neurol Disord · 2024
PMID: 38532802Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Patisiran (substance)
SNOMED CT
773605008
UMLS CUI
C3896714
RxNorm CUI
2053490

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Patisiran — Conditions, Biomarkers & Specialists | Ltrl | Ltrl